The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma

Everolimus is an oral agent that targets the mammalian target of rapamycin (mTOR) pathway. This study investigated mTOR pathway activation in T-cell lymphoma (TCL) cell lines and assessed antitumor activity in patients with relapsed/refractory TCL in a phase 2 trial. The mTOR pathway was activated i...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Blood
Glavni autori: Witzig, Thomas E., Reeder, Craig, Han, Jing Jing, LaPlant, Betsy, Stenson, Mary, Tun, Han W., Macon, William, Ansell, Stephen M., Habermann, Thomas M., Inwards, David J., Micallef, Ivana N., Johnston, Patrick B., Porrata, Luis F., Colgan, Joseph P., Markovic, Svetomir, Nowakowski, Grzegorz S., Gupta, Mamta
Format: Artigo
Jezik:Inglês
Izdano: American Society of Hematology 2015
Teme:
Clinical Trials and Observations
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4504947/
https://ncbi.nlm.nih.gov/pubmed/25921059
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2015-02-629543
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items